During the past decade, Miami Dermatology and Laser Research conducted 30 clinical trials. In the 10-year time frame, 30 clinical trials started and 9 clinical trials were completed, i.e. on average, 30% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 8 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Miami Dermatology and Laser Research" #1 sponsor was "Eli Lilly and Company" with 10 trials, followed by "Cytrellis Biosystems, Inc." with 4 trials sponsored, "Sebacia, Inc." with 3 trials sponsored, "Pfizer" with 2 trials sponsored and "Avita Medical" with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Miami Dermatology and Laser Research" #1 collaborator was "Dermira, Inc." with 2 trials as a collaborator, "Incyte Corporation" with 2 trials as a collaborator, "Nektar Therapeutics" with 2 trials as a collaborator, "Alira Health" with 1 trials as a collaborator and "Emblation Limited" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Miami Dermatology and Laser Research" are "Atopic Dermatitis" (6 trials), "Acne Vulgaris" (2 trials), "Dermatitis, Atopic" (2 trials), "Laxity; Skin" (2 trials) and "Psoriasis" (2 trials). Many other conditions were trialed in "Miami Dermatology and Laser Research" in a lesser frequency.

Most popular intervention types in "Miami Dermatology and Laser Research" are "Device" (14 trials), "Drug" (14 trials), "Biological" (2 trials), "Other" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Lebrikizumab" (3 trials), "MCD" (3 trials), "Abrocitinib 200 mg" (2 trials) and "Baricitinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Miami Dermatology and Laser Research" are 29 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Miami Dermatology and Laser Research". undefined are not yet recruiting, 3 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Miami Dermatology and Laser Research, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Miami Dermatology and Laser Research, 3 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 14 trials that are defined as “Not Applicable".